AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02208544 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Thyroid Surgery
Description: Diagnostic Thyroid Surgery
Study NCT02208544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound of the head and neck
Description: Confirmatory Neck Ultrasonography in FDG-PET/CT negative patient in the experimental arm
Study NCT02208544 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: FDG-PET/CT
Description: Head and Neck FDG-PET/CT
Study NCT02208544 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Description: Head and Neck FDG-PET/CT
Study NCT01205347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 80mg
Description: Simvastatin 80mg once a day
Study NCT01205347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 10mg
Description: Simvastatin 10mg once a day
Study NCT00128661 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine
Description: Three doses of Cervarix vaccine administered on a 0, 1, 6-month schedule
Study NCT00128661 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hepatitis A inactivated virus vaccine
Description: Three doses of Havrix vaccine administered on a 0, 1, 6-month schedule
Study NCT04202497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-418
Description: TAK-418 orally.
Study NCT04202497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-1054 (radiotracer)
Description: \[18F\]MNI-1054 injection.
Study NCT01518569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ulinastatin
Description: ulinastatin 5000 unit/kg iv before the initiation of CPB
Study NCT01518569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (the same amount of normal saline) iv before the initiation of CPB
Study NCT03119948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Placebo in soleus and placebo in rectus femoris, and placebo in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.~150U (x 7.5 ml) placebo Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) placebo distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment
Study NCT03119948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin injection
Description: Botulinum toxin type A in soleus and in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.~150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) Xeomin® 20U/ml RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment.
Study NCT03119948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo injection and botulinum toxin injection
Description: Botulinum toxin type A in soleus and placebo in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus..~150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment.
Study NCT05545176 — intervention group
Intervention type: OTHER
Intervention: termination of resuscitation rules
Description: Use retrospective data to analyze the accuracy termination of resuscitation rules and further develope a termination of resuscitation rule.
Study NCT03857698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative Physical Therapy
Description: Patients who were discharged from the hospital and received the sutures will be supervised 2 days a week for 8 weeks. Exercise programs will be promoted individually.~* Ice application for pain, edema control~* Patellar mobilization~* Three-way straight leg lifting exercises~* Isometric exercises around the hips and knees~* Active assisted, active, resistant knee range of motion exercises~* Heel shift exercises in supine and sitting~* Hip abduction on the side lying~* Stretching exercises for patients with gastrosoleus, hamstring, hip flexor muscles~* Neuromuscular Electrical Stimulation (NMES) for quadriceps muscle of patients will be applied. The isometric quadriceps contraction observed during the procedure will be required to actively participate in the patients.
Study NCT03857698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Stabilization Exercise
Description: In the first session, breathing control and alet abdominal hallawing of movement will be taught to the patients with the help of the pressure biofeedback device. The degree of difficulty of the exercises will be improved by using different positions, by adding rotations to the motion, making the pelvic control more difficult and increasing the number of repetitions. In case of exacerbation of symptoms, the level will not be advanced. Exercises will be advanced according to the patient's initial level and response to exercise.~* Consecutive shoulder flexion and extension in supine~* Building a bridge~* Lower body and hip flip~* Single leg extension with bilateral arm elevation~* Resilient leg stretch with bilateral arm elevation~* Hip external rotation in lateral hospitalization~* Side-lying arm opening~* Shoulder girdle retraction on ball, horizantal abduction and extension
Study NCT03668639 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Weekly administration of dexamethasone 12 mg Day 1, 8 mg Day 2-3, and 4 mg Day 4 for five weeks.
Study NCT02420197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity resistance training
Study NCT02420197 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General physical activity
Study NCT02420197 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary rehabilitation program
Study NCT02420197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation program
Study NCT01908504 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PET-CT
Description: At radiation planning subjects will have a PET-CT. The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
Study NCT01020877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Vaginal Gel, 0.75%
Study NCT01020877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Vaginal Gel, 0.75%
Study NCT01088984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Study NCT01201577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium longum BB536
Description: 2 capsules od
Study NCT01201577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active hexose correlated compound (AHCC)
Description: One capsule tds
Study NCT01201577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium longum BB536 and Active hexose correlated compound (AHCC)
Description: One capsule tds (prebiotic) and two capsules od (probiotic)
Study NCT01201577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn starch placebo capsule
Description: One capsule tds and two capsules od
Study NCT01201577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin
Description: 250mg od
Study NCT01201577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 250mg od
Study NCT01982305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simulator
Description: Axillary nerve anatomy lecture plus training with the simulator.
Study NCT01982305 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cadaver
Description: Axillary nerve anatomy lecture plus training with the cadaver model.
Study NCT04730141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient mobilization with pre-operative mobilization training and mobilization protocol
Description: Postoperative mobilization for the first 24 hours
Study NCT03245905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 30mg orally BIW. Treatment cycles are repeated every 3 weeks.The maximum duration of treatment is 2 years.
Study NCT03610711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg administered IV over 30 minutes every 2 weeks for one year
Study NCT03610711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: every 2 weeks for one year
Study NCT01006980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 960 mg (as 240 mg tables) orally twice daily
Study NCT01006980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: 1000 mg/m2 intravenously every 3 weeks
Study NCT03795753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F2S Communicator
Description: The communicator will be attached to the BPAP/CPAP mask. The study coordinator will ENABLE the communicator. A list of single words and 5-word through 15-word sentences will be provided to the patient. Each single word may be read aloud up to two times. The partner must then select the read word out of a list of twelve possible words. Each sentence may be read aloud up to two times. The partner must transcribe each sentence on a standardized form. A survey will be provided to evaluate the mask on, communicator on period.
Study NCT03795753 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-functioning Communicator
Description: The communicator will be attached to the BPAP/CPAP mask. The study coordinator will DISABLE the communicator. A list of single words and 5-word through 15-word sentences will be provided to the patient. Each single word may be read aloud up to two times. The partner must then select the read word out of a list of twelve possible words. Each sentence may be read aloud up to two times. The partner must transcribe each sentence on a standardized form. A survey will be provided to evaluate the mask on, communicator on period.
Study NCT03438357 — intervention group
Intervention type: OTHER
Intervention: Analysis of cerebral MRI with automatic segmentation software
Description: Pixyl.Neuro software versus manual analysis of lesions
Study NCT00835744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: clomiphene citrate
Description: ovulation induction
Study NCT00835744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gonadotropins
Description: ovulation induction
Study NCT01692951 — intervention group
Intervention type: OTHER
Intervention: serum sample
Description: Serum samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment. Serum samples of control subjects were collected from a biobank
Study NCT00237731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Description: morphine 0.05
Study NCT00237731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: morphine 0.10
Study NCT02869529 — intervention group
Intervention type: OTHER
Intervention: Data collection
Study NCT01185275 — intervention group
Intervention type: DEVICE
Intervention: Alair system
Description: Bronchial thermoplasty
Study NCT03867695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: At the end of the lobectomy VATS procedure, 0,5 mL/kg of 0.375% ropivacaine will be administered.
Study NCT03867695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile saline
Description: Patients will receive a placebo injection with 0,5 mL/kg of sterile normal solution
Study NCT03425097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: Fexofenadine 180 mg in the morning
Study NCT03425097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Cap
Description: Placebo cap in the morning
Study NCT00515671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery
Description: a structured curriculum to help mental health consumers manage their illnesses and pursue goals related to recovery from mental illness
Study NCT00515671 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Problem Solving
Description: Weekly problem-solving support group
Study NCT04631159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health2Sync app and report blood glucose data weekly
Description: Patients will need to download and use the Health2Sync app and report blood glucose data weekly
Study NCT04631159 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: self-manage
Description: Patients will be asked to self-manage and there is no intervention during the tracking process
Study NCT04604574 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Indigenous Healing and Seeking Safety
Description: Indigenous Healing and Seeking Safety Intervention: Initial 90-minute meetings will be conducted with the participants; during these meetings, participants will receive information about IHSS, traditional healing, sharing circles, sweat lodge ceremonies, and program details. The sharing circles will take place at Benbowopka Residential treatment Centre in Blind River, Ontario. Each of the sharing circles will be cofacilitated by two Indigenous health-care workers. These facilitators will organize and lead sharing circles daily throughout the 28-day treatment cycle. Each sharing circle will be two hours long. The Seeking Safety program consists of up to 25 treatment topics that aim to teach participants a variety of skills. The majority of topics address the cognitive, behavioral, interpersonal, and case management needs of persons with SUD and posttraumatic stress disorders (PTSD) (Najavits, 2002a). The treatment will adhere to the concept of Two-Eyed Seeing and cultural sensitivity.
Study NCT04542213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin tablet
Description: Linagliptin 5mg once daily plus a basal-bolus insulin scheme
Study NCT04542213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Basal-bolus insulin scheme
Study NCT02622243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: long acting muscarinic antagonist
Study NCT02622243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycopyrronium
Description: long acting muscarinic antagonist
Study NCT02622243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: inhaler device used to deliver active tiotropium or placebo
Study NCT02622243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breezehaler
Description: inhaler device used to deliver active glycopyrronium or placebo
Study NCT02488226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gaze-contingent eye-tracking technology
Description: When participants look away from a prototypical or expected norm, their gaze patterns are redirected to those prototypical locations.
Study NCT01674829 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MA09-hRPE
Description: Transplantation of MA09-hRPE cells accoding to the assigned dose group
Study NCT02944201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol will give twice daily until prostatectomy
Study NCT05246891 — intervention group
Intervention type: OTHER
Intervention: rehabilitation nursing
Description: Functional respiratory rehabilitation and motor exercise plan.
Study NCT01878903 — intervention group
Intervention type: OTHER
Intervention: Electronic VAS
Description: Post-opearive pain patients will be assessed using electional VAS and verbal NRS
Study NCT05398406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAP Block group
Description: TAP Block: the US probe was placed on the imaginary line connecting the anterior superior iliac spine and the umbilicus. The ilioinguinal and iliohypogastric nerves in the fascia of the internal obliq and transverse abdominis muscles were visualized by US. A total of 40 ml of local anesthetic was infiltrated ESP Blok : a 100 mm 21G peripheral nerve block needle was inserted between the erector spinae muscle and the transverse process structures in an in-plane section guided by US from the T7-8 level. 40 ml of the prepared solutions were injected PVB: In the lateral decubitus position, the cranial to caudal transverse processes and the superior costotransverse ligament and the pleura were visualized from the T7-8 level in the in-plane section under US guidance. A 100 mm 21G peripheral nerve block needle was advanced until it passed through the superior costotransverse ligament. A total of 40 ml of injections were made
Study NCT05398406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paravertebral block group
Description: In the lateral decubitus position, the cranial to caudal transverse processes and the superior costotransverse ligament and the pleura were visualized from the T7-8 level in the in-plane section under US guidance. A 100 mm 21G peripheral nerve block needle (SonoPlex Stim Cannula, PAJUNK®, USA) was advanced until it passed through the superior costotransverse ligament. A total of 40 ml of injections were made bilaterally in the form of 20+20 ml.
Study NCT05398406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erector spinae block group
Description: In the lateral decubitus position, a 100 mm 21G peripheral nerve block needle (SonoPlex Stim Cannula, PAJUNK®,USA) was inserted between the erector spinae muscle and the transverse process structures in an in-plane section guided by US from the T7-8 level. A total of 40 ml of the prepared solutions were injected bilaterally as 20+20 ml.
Study NCT00568178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan Potassium
Description: Losartan Use During the Double-Blind Treatment Phase:~Losartan potassium was administered orally as tablets; 25 or 50 milligrams (mg); or as a liquid suspension 2.5 mg/mL prepared for participants who weighed less than 25 kilograms (kg) or for those participants unable to swallow tablets. During the double-blind period, participants were initially randomized to either a once-daily weight-dependent dose of approximately 0.7 mg/kg (25 mg tablet; up to 50 mg per day) and at 2-weeks the dose was increased to a once-daily maximum weight-dependent dose of 1.4 mg/kg. The maximum dose of losartan, as specified in the protocol, was 50 mg/day (if the patient weighed \<50 kg)~or 100 mg/day (if the patient weighed ≥50 kg).~Losartan Use During the Treatment Extension Phase:~Dose modifications of the drug were left up to the discretion of the Investigators based on each participant's level of tolerance.
Study NCT00568178 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo (Losartan)
Description: Placebo (losartan suspension), administered orally, once daily for 12 weeks
Study NCT00568178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo (Losartan)
Description: Placebo (losartan suspension), administered orally, once daily for 12 weeks
Study NCT00568178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: amlodipine besylate
Description: Amlodipine besylate (1 mg/mL) liquid suspension, oral administration, titrated to 0.2 mg/kg/day (5 mg maximum dose) per day for 12 Weeks
Study NCT00568178 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo (amlodipine besylate)
Description: Liquid suspension, 1mg/mL, titrated to 0.2 mg/kg/day (5 mg maximum dose) once daily, for 12 weeks
Study NCT00568178 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Losartan)
Description: Normotensive patients randomized to losartan placebo for 12 weeks.
Study NCT00568178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril Maleate
Description: Enalapril 2.5-, 5-, 10-, and 20-mg tablets or enalapril suspension (1 mg/mL), oral administration, once daily for 36 months.
Study NCT04448119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Favipiravir is the experimental drug. The dosage for favipiravir to be used in this study for prophylaxis is 1600 mg (8 x 200 mg tablets) orally twice daily on day 1 followed by 800 mg (4 x 200 mg tablets) orally twice daily on days 2-25. The dose of favipiravir for treatment is 2000 mg orally twice daily on day 1, the 1000 mg orally twice daily for 13 additional days.